Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Catalent Pharma Solutions, LLC
483
•Catalent Pharma Solutions, LLC•April 22, 2025

Catalent Pharma Solutions, LLC – FDA 483, Apr 22, 2025

Record Details

An unnamed pharmaceutical manufacturing firm received an FDA Form 483 following an inspection conducted from April 14 to April 22, 2025. The inspection, led by Geoffrey K. Kilili, identified significant deviations from regulatory requirements under Christopher M. Rosenbaum, General Manager. The primary concerns revolved around two key areas. Firstly, the firm failed to adequately review unexplained discrepancies and batch specification failures. Specifically, there was an absence of a robust environmental monitoring program for HEPA-filtered process air, and no established microbial limits for such air. An investigation into mold contamination in drug product granulation in June 2021 revealed Fusarium sporotrichioides in process air. Despite this, the firm failed to expand the investigation to other systems or implement periodic microbial monitoring for process air, raising concerns about potential ongoing contamination. Secondly, the firm did not adhere to its written procedures for equipment cleaning and maintenance. An instance on March 18, 2025, showed a fluid bed processor identified as clean despite containing a pool of stale, black/grey liquid at the bottom of its air inlet. This directly contradicted the firm's own procedures requiring visual inspection and verification of dryness and absence of residue. These observations indicate a need for the firm to implement comprehensive corrective actions to ensure compliance with good manufacturing practices and prevent potential product contamination and quality issues. The FDA expects a thorough response addressing each observation.

Company
Catalent Pharma Solutions, LLC
Inspection date
April 22, 2025
Product type
drugs
Office
Cincinnati District Office
People
  • Christopher M. Rosenbaum (General Manager)
  • Geoffrey K. Kilili (investigator)
View Company Profile

ID · 8fba6d96-b5ce-4dd0-9801-cdd4fe61f210

Other documents for Catalent Pharma Solutions, LLC
  • 483 - 2023-01-11January 11, 2023
  • EIR - 2021-08-02August 2, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Catalent Pharma Solutions, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.